Clinical trial · Observational
Right Ventricular Function in Patients Taking Carfilzomib
Right Ventricular Function of Patients With Multiple Myeloma Treated With Carfilzomib
NCT06568952CI-TRIAL-00080137completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients treated for multiple myeloma in the second line with carfilzomib may develop pulmonary hypertension. This is well documented in the literature. However, there are no studies looking at right ventricular function in these patients, both before and during treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pulmonary Hypertension | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- tricuspid annular plane systolic excursion
- timeFrame
- 6 months after carfilzomib treatment
- description
- measurement of tricuspid annular plane systolic excursion by echocardiography
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients treated for multiple myeloma with carfilzomib * Patients with echocardiogram before and under treatment. Exclusion Criteria: * /
References
Publications (0)
Data not yet available
No reference posted for this study.